US approves new HIV drug
Tuesday 24 May 2011
The US Food and Drug Administration on Friday approved a new drug, Edurant, to fight HIV in combination with other antiretrovirals already on the market.
Made by the New Jersey based Tibotec Therapeutics, Edurant helps block the virus from replicating and is part of a class of drugs known as non-nucleoside reverse transcriptase inhibitor.
The pill is to be taken once daily with food, the FDA said.
"Patients may respond differently to various HIV drugs or experience varied side effects," said Edward Cox, director of the office of antimicrobial products in the FDA's Center for Drug Evaluation and Research.
"FDA's approval of Edurant provides an additional treatment option for patients who are starting HIV therapy."
The approval followed phase II and II trials that showed that patients who had not received previous therapy saw an 83 percent lower viral load after they took Edurant along with other antiretroviral drugs.
Side effects included depression, insomnia, headache and rash.
Life & Style blogs
WWE 2K15 gameplay trailer: First look at Sting, Triple H and Daniel Bryan in next-gen graphics
Maytree charity: Sanctuary for the suicidal - one mother's story
iOS 8 apps and features: eight iPhone settings you need to look at after you install the update
iPhone 'Wave': iOS 8 hoax claims you can charge your iPhone in the microwave - you can't
First day of Autumn: Google Doodle celebrates 2014 Autumn equinox
- 1 Cyclist in Russia narrowly misses being hit by car and lorry
- 2 Y-40 Deep Joy: The world's deepest swimming pool
- 3 'F*ck it, I quit': KTVA reporter Charlo Greene quits live on air in spectacular fashion
- 4 Syria air strikes: President Obama undergoes Damascene conversion as Isis forces America to change tack
- 5 Pink Floyd new album: Band unveil cover art for first record in 20 years
£16500 - £20000 Per Annum: Clearwater People Solutions Ltd: We are currently r...
£100 - £125 per day: Randstad Education Crawley: KS2 PPA Teacher currently nee...
£40000 - £45000 per annum + pension, healthcare,25 days: Ashdown Group: An est...
£28000 per annum: Ashdown Group: IT Software Application Support Analyst - Imm...